Georgia patients infected with isoniazid-monoresistant tuberculosis strain have a similar response to treatment as patients with drug-susceptible tuberculosis, according to a recent study led by a PhD student at Georgia State University School of Public Health.
Isoniazid-monoresistant tuberculosis, or INH-monoresistant TB, is the most common drug-resistant TB in the United States. However, little is known about the characteristics of patients with INH-monoresistant TB and their treatment outcomes in the state of Georgia because previous studies have used macro-level data from the U.S. and other countries, such as India and Israel.
The state-level study “did not find evidence to suggest that patients with isoniazid-monoresistant tuberculosis required altered treatment considerations,” the researchers concluded
To better determine what factors are associated with the disease and its response to treatment, researchers studied all patients with TB who were 15 and older from 2009 – 2014, using the Georgia State Electronic Notifiable Disease Surveillance System (SENDSS). Among 1,141 eligible patients, 998 had drug-susceptible TB, while 143 had INH-monoresistant TB.
The study found that being male and having a history of homelessness were associated with greater odds of having INH-monoresistant TB. The study also highlighted that the risk of poor treatment outcomes were similar among TB patients with and without INH-monoresistance.
The results of the study are published in the Annals of the American Thoracic Society in the article “Isoniazid-Monoresistance and Rate of Culture Conversion among Confirmed Tuberculosis Patients in the State of Georgia, 2009 – 2014.” The study’s lead author is Ms. Argita Salindri, a Georgia State PhD student in the School of Public Health and former TB program assistant in the Division of Health Protection at the Georgia Department of Public Health.
The study’s authors also include Dr. Matthew Magee, assistant professor of epidemiology and biostatistics at Georgia State; Dr. Rose-Marie F. Sales, TB Program director at the Georgia Department of Public Health; Dr. Lauren DiMiceli, an epidemiologist at the Georgia Department of Public Health; and Dr. Marcos C. Schechter and Dr. Russell R. Kempker with Emory University School of Medicine.